CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Vandetanib 300mgdrug
Likely dose
Vandetanib 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01661179
NCT01661179Phase 2Completed
CompareCT.gov

A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma

Genzyme, a Sanofi Company·interventional·Posted Aug 9, 2012·Updated Dec 5, 2016

In Brief

A Phase 2 clinical trial evaluating Vandetanib 300mg for Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma. Completed, enrolled 14 participants across 4 sites.

Detailed Summary

Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2012
Enrollment StartNov 1, 2012
Primary CompletionDec 1, 2013
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.9 years ago

Interventions

Vandetanib 300mgdrug

300 mg oral dose once daily (100 mg x 3 tablets)